.tb-field[data-toolset-blocks-field="203299a22ab9b4467746e3ecd5032d31"] { font-size: 14px; }  h3.tb-heading[data-toolset-blocks-heading="c64a8eae195c288bfd5aec4150db92c6"]  { font-size: 16px; }  .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="cdfd4c4737b2898eba4443dd59a1bf50"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="ed3832aa6201cbec5b1e5b902dc067e2"] { padding: 25px; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { background-color: rgba( 243, 241, 241, 1 );border-radius: 3px;padding: 10px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 221, 219, 219, 1 );display: flex; } .tb-field[data-toolset-blocks-field="b4905723ecea41184171014c65948a9a"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="c949bea6c10cb48f79d87a6418026524"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="f8b4df145ada4a882c0769270c620213"] { font-size: 12px;line-height: 16px;padding: 0px;margin: 0px; }  .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} @media only screen and (max-width: 781px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } @media only screen and (max-width: 599px) {   .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="e8c9eb677ef767ba4b4b41b7617e0983"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="19e1e13dfc2b82cdc91936dd659e218d"] { display: flex; }    .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}  } 

Bio-Rad

Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development

Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq)...

Bio-Rad Launches ddSEQ Single-Cell 3′ RNA-Seq Kit for Single-Cell Gene Expression

ddSEQ single-cell 3' RNA-Seq kit and Omnition v1.1 analysis software enable high-quality and affordable single-cell transcription and gene expression to support molecular biology, oncology and drug discovery research 19 June 2024 -- California, US -- Bio-Rad Laboratories, a global leader in life sciences research and clinical diagnostics products, today announced the launch of the ddSEQ...

Bio-Rad Announces Collaboration Agreement with Oncocyte to Commercialise Transplant Monitoring with Droplet Digital PCR

The collaboration aims to provide researchers with cutting-edge tools to enable transformational monitoring of key biomarkers in solid tissue transplants 12 April 2024 -- California, US -- Bio-Rad Laboratories, a global leader in life sciences research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation, a precision diagnostics company, to develop and...

Bio-Rad Launches First Ultrasensitive Multiplexed Digital PCR Assay for Breast Cancer Mutation Detection in Clinical Research

Highly Sensitive and Multiplexed Assay for the Detection, Discrimination and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600 Droplet Digital PCR System 2 April 2024 -- California, US -- Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, today announced the launch of its first...

Bio-Rad launches validated antibodies for Rare Cell and Circulating Tumour Cell Enumeration

Antibodies Validated for Use with Bio-Rad’s Celselect Slides Enumeration Stain Kits to Enable Immunostaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples 26 March 2024 – Hercules, CA, US – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated...

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring 5 October 2023 -- California, US -- Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six...

Bio-Rad Launches PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers

Superior thermal performance and enhanced usability for PCR applications, such as sequencing, cloning and genotyping. 28 September 2023 -- California, US -- Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, today announced the launch of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, designed to support PCR applications...

Bio-Rad Launches EconoFit Chromatography Column Packs

HERCULES, California, June 28, 2022: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of EconoFit Low-Pressure Prepacked Chromatography Column Packs to support resin screening experiments in the development of protein purification workflows.